-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ziv-aflibercept
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ziv-aflibercept Drug Details Ziv-aflibercept (Zaltrap / Aflitiv / Lidaveg / Zaltrapziv / Zalzen) is...
-
Sector Analysis
PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2025
The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS...